3.1 Levels of serum IL-6, IL-10, and TGF-β in SFTS and COVID-19
patients.
Among SFTS patients, serum IL-6 and IL-10 concentrations in those with
fatal disease were significantly higher than those in patients with
nonfatal disease, and TGF-β concentrations in the former were
significantly lower than those in the latter during the initial clinical
course of hospitalization (Figure 1 and Supplemental
table 3 ).
However, there were no statistically significant differences in serum
levels of IL-2, IL-4, IL-17A, IFN-γ, and TNF-α between patients with
fatal disease and those with nonfatal disease (Supplemental
figure 1 and Supplemental table 3 ).[7]
In COVID-19 patients, serum IL-6 and IL-10 concentrations in patients
with severe and critical disease were significantly higher than those in
patients with mild to moderate disease, and TGF-β concentrations in
patients with severe and critical disease were significantly lower than
those in patients with mild to moderate disease during the initial
clinical course of hospitalization (Figure 2 andSupplemental table 4 ).
However, similar to the results of SFTS patients, there were no
statistically significant differences in plasma levels of IL-2, IL-4,
IL-17A, IFN-γ, and TNF-α between patients with mild to moderate and
severe/critical disease (Supplemental figure 2 andSupplemental table 4 ).
In this study, we found that the levels of serum IL-6, IL-10, and TGF-β
were significantly associated with the outcomes of patients with SFTSV
and SARS-CoV-2 (Figures 1 and2 ).[7, 9, 10, 14, 15].